Evidence map›Paper›PMID 28186984›Full record

SynthesisOncotarget2017

Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis.

Zenglin Pei, Song-Mei Liu, Jing-Tao Huang, Xuan Zhang, Dong Yan, Qianlin Xia, Chunxia Ji, Weiping Chen, Xiaoyan Zhang, Jianqing Xu and 1 more

Open access · diamondAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Circulating microRNAs: Challenges with their use as liquid biopsy biomarkers.Cancer biomarkers : section A of Disease markers · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Zenglin PeiScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, P.R. China.
Song-Mei LiuCenter for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Jing-Tao HuangCenter for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Xuan ZhangScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, P.R. China.
Dong YanDepartment of Medical Oncology, Beijing Chaoyang Hospital affiliated to Capital Medical University, Beijing, China.
Qianlin XiaScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, P.R. China.
Chunxia JiScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, P.R. China.
Weiping ChenGenomics Core, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Xiaoyan ZhangScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, P.R. China.
Jianqing XuScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, P.R. China.
Jin WangScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, P.R. China.
Shanghai Public Health Clinical Center · CNCapital Medical University · CNNational Institute of Diabetes and Digestive and Kidney Diseases · USWuhan University · CNZhongnan Hospital of Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic cancer (PaCa) is the most lethal gastrointestinal (GI) tumor. Although many studies on differentially expressed miRNAs as candidate biomarkers of pancreatic cancer have been published, reliability of these findings generated from investigations performed in single laboratory settings remain unclear.

resultsThere were 29 articles with a total of 2,225 patients and 1,618 controls included in this meta-analysis. The pooled sensitivity was 82% (95% CI, 79-85%); the specificity was 85% (95% CI, 79-89%); and area under the curve (AUC) was 0.89 (95% CI, 0.86-0.92). Subgroup analyses indicated that there were significant divergences between Caucasian and Asian subgroups for circulating miRNA analysis. MATERIALS AND

methodsTo comprehensively investigate the potential utility of miRNAs as biomarkers of the disease, we searched publications diagnosing PaCa using miRNAs from PubMed, Medline, Embase, Google Scholar and Chinese National Knowledge Infrastructure (CNKI) databases. The sensitivity (SEN), specificity (SPE), and summary receiver operating characteristic (SROC) curve were used to examine the overall test performance, and heterogeneity was analyzed with the I2 test.

conclusionsOur analysis demonstrated that multiple miRNAs (SEN: 85%; SPE: 89%; AUC: 0.93) were more accurate for diagnosing PaCa than a single miRNA (SEN: 78%; SPE: 79%; AUC: 0.84), and future studies are still needed to confirm the diagnostic value of these pooled miRNAs for PaCa.

Indexed as

Biomarkers, TumorCase-Control StudiesHumansMicroRNAsPancreatic NeoplasmsPrognosisBiomarkers, TumorMicroRNAsdiagnosticsmeta-analysismultiple miRNApancreatic cancerSROC

Identifiers

PMID28186984
PMCPMC5410249
OpenAlexW2587206047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.